dacomitinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5297 1110813-31-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dacomitinib
  • dacomitinib hydrate
  • vizimpro
  • PF-00299804-03
  • PF-00299804
  • PF-299
  • PF-299804
  • PF-804
Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations.
  • Molecular weight: 469.95
  • Formula: C24H25ClFN5O2
  • CLOGP: 5.75
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 2
  • TPSA: 79.38
  • ALOGS: -4.73
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 4, 2019 EMA PFIZER EUROPE MA EEIG
Sept. 27, 2018 FDA PFIZER INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EB07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:74440 egfr inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer, positive for epidermal growth factor receptor expression indication 426964009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.02 acidic
pKa2 9.12 Basic
pKa3 4.78 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
15MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2023 NEW CHEMICAL ENTITY
30MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2023 NEW CHEMICAL ENTITY
45MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2023 NEW CHEMICAL ENTITY
15MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2025 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
15MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
30MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2025 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
30MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
45MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2025 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
45MG VIZIMPRO PFIZER N211288 Sept. 27, 2018 RX TABLET ORAL Sept. 27, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase INHIBITOR IC50 8.22 SCIENTIFIC LITERATURE DRUG LABEL
Receptor tyrosine-protein kinase erbB-2 Kinase INHIBITOR IC50 7.34 SCIENTIFIC LITERATURE DRUG LABEL
Receptor tyrosine-protein kinase erbB-4 Kinase INHIBITOR IC50 7.13 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
1042385-75-0 SECONDARY_CAS_RN
4037910 VANDF
C2987430 UMLSCUI
CHEBI:132268 CHEBI
1C9 PDB_CHEM_ID
CHEMBL2105719 ChEMBL_ID
CHEMBL2110732 ChEMBL_ID
DB11963 DRUGBANK_ID
D09883 KEGG_DRUG
C525726 MESH_SUPPLEMENTAL_RECORD_UI
11511120 PUBCHEM_CID
7422 IUPHAR_LIGAND_ID
5092U85G58 UNII
2058849 RXNORM
293963 MMSL
35285 MMSL
d08999 MMSL
017767 NDDF
781492009 SNOMEDCT_US
781495006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vizimpro HUMAN PRESCRIPTION DRUG LABEL 1 0069-0197 TABLET, FILM COATED 15 mg ORAL NDA 28 sections
Vizimpro HUMAN PRESCRIPTION DRUG LABEL 1 0069-1198 TABLET, FILM COATED 30 mg ORAL NDA 28 sections
Vizimpro HUMAN PRESCRIPTION DRUG LABEL 1 0069-2299 TABLET, FILM COATED 45 mg ORAL NDA 28 sections
Vizimpro HUMAN PRESCRIPTION DRUG LABEL 1 63539-197 TABLET, FILM COATED 15 mg ORAL NDA 27 sections